Johnson & Johnson Stock News

Johnson & Johnson (JNJ) closed at $145.97 in the latest trading session, marking a -1.24% move from the prior day.

J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaq

With a wild positive finish on the last trading day of May 2024, thanks in part to some decent inflation data, investors now set their sights on the summer months. While it was a somewhat nail-biting

CNBC's Jim Cramer delivers his daily Mad Dash.

If you are worried about the economy and how the market will move from here, it is ideal to invest in dividend stocks that pay, no matter the market situation. When you have dividend aristocrat sto

PORTLAND, Ore.--(BUSINESS WIRE)--A jury in Portland, Ore., has found in favor of a mother of three suffering from the deadly cancer mesothelioma and ordered Johnson & Johnson to pay her $260 million.

Johnson & Johnson must pay $260 million in the case of an Oregon woman who said she got mesothelioma from inhaling the company's talc powder, a jury found on Monday.

Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks, including Johnson & Johnson, Costco, and Spotify.

Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their sh

The Johnson & Johnson CEO discusses the company's plan to pay $6.5 billion to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer. Those c

CNBC's Angelica Peebles and Johnson & Johnson CEO Joaquin Duato join 'Squawk on the Street' to discuss the company's goals in oncology, the future of cancer treatments, state of the talc lawsuits, dru

The financial media does its best to keep you informed about what's happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards.

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr